Want to see TSE:MBX full AI Analyst Report?
MBX Stock Chart & Stats
C$0.32
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.32
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.21 - C$0.33
Previous CloseN/A
Volume7.02K
Average Volume (3M)29.55K
Market Cap
C$41.78M
Enterprise ValueC$40.83
Total Cash (Recent Filing)C$7.16M
Total Debt (Recent Filing)C$6.72M
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Dec 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding136,968,660
10 Day Avg. Volume19,903
30 Day Avg. Volume29,551
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.33
Price to Sales (P/S)1.98
P/FCF Ratio-42.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.40Price Target Upside25.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)C$18.30M
Bulls Say, Bears Say
Bulls Say
Diagnostic Product And Recurring Channel GrowthGrowth across antigens, CAPs and direct clinical-lab sales broadens demand beyond individual contracts. The expanding B2C channel is becoming a seven-figure recurring revenue stream, supporting customer diversification and more repeatable long-term sales.
Process Improvements Support ScalabilityHigher yields, automation and better product mix can improve unit economics as production scales. These operational changes may help restore margin durability and reduce the effect of fixed manufacturing costs on future profitability.
Manageable Leverage Preserves Financial FlexibilityModerate leverage means the company is not heavily debt-funded, limiting interest and refinancing pressure while operations recover. This provides greater flexibility to fund production expansion and regulatory programs than a highly leveraged balance sheet would.
Bears Say
Persistent Losses And Cash ConsumptionThe company currently consumes cash rather than funding itself internally, while losses reduce financial resilience. Sustained negative cash flow could require additional financing or constrain investment in production, commercialization and regulatory initiatives.
Margin Compression And Weak Operating LeverageRevenue recovery has not yet translated into durable profitability, indicating cost pressure and weaker operating leverage. If margins remain below historical levels, additional sales may generate insufficient contribution to cover operating expenses and cash needs.
International And Customer-timing DependenceThe sharp China decline and reliance on international customers expose revenue to regional demand changes and procurement conditions. Client-controlled timelines can also delay large contract conversions, making recovery uneven and reducing earnings visibility.
Microbix Biosystms News
MBX FAQ
What was Microbix Biosystms J’s price range in the past 12 months?
Microbix Biosystms J lowest stock price was C$0.21 and its highest was C$0.33 in the past 12 months.
What is Microbix Biosystms J’s market cap?
Microbix Biosystms J’s market cap is C$41.78M.
When is Microbix Biosystms J’s upcoming earnings report date?
Microbix Biosystms J’s upcoming earnings report date is Dec 17, 2026 which is in 83 days.
How were Microbix Biosystms J’s earnings last quarter?
Microbix Biosystms J released its earnings results on Aug 13, 2026. The company reported -C$0.006 earnings per share for the quarter.
Is Microbix Biosystms J overvalued?
According to Wall Street analysts Microbix Biosystms J’s price is currently Undervalued.
Does Microbix Biosystms J pay dividends?
Microbix Biosystms J does not currently pay dividends.
What is Microbix Biosystms J’s EPS estimate?
Microbix Biosystms J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microbix Biosystms J have?
Microbix Biosystms J has 136,968,660 shares outstanding.
What happened to Microbix Biosystms J’s price movement after its last earnings report?
Microbix Biosystms J reported an EPS of -C$0.006 in its last earnings report. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Microbix Biosystms J?
Currently, no hedge funds are holding shares in TSE:MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Microbix Biosystms J
Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.
MBX Stock 12 Month Forecast
Average Price Target
C$0.40
▲(25.00% Upside)
Technical Analysis
BriaCell Therapeutics
―
Resverlogix
―
Devonian Health Group
―
Defence Therapeutics
―
Thiogenesis Therapeutics Corp
―